Cidara Therapeutics has been granted a patent for a method of treating invasive candidiasis using CD101, a pharmaceutical composition. The method involves intravenously administering specific doses of CD101 over a period of time. The patent also covers pharmaceutical compositions, methods, and kits featuring CD101. GlobalData’s report on Cidara Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Cidara Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Cidara Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Cidara Therapeutics's grant share as of September 2023 was 27%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for a method of treating invasive candidiasis

Source: United States Patent and Trademark Office (USPTO). Credit: Cidara Therapeutics Inc

A recently granted patent (Publication Number: US11712459B2) describes a method for treating invasive candidiasis, specifically candidemia, in a subject. The method involves the administration of CD101, a drug, in salt or neutral form, through intravenous infusion.

The first claim of the patent outlines two possible treatment regimens. In the first regimen, the subject is given a first dose of 400 mg of CD101 on day 1, followed by a second dose of 200 mg on day 8. Optionally, a third dose of 200 mg can be administered on day 15. The CD101 is administered as an aqueous pharmaceutical composition over a time period of 30 to 180 minutes.

The second regimen involves a higher dosage of CD101. The subject is given a first dose of 400 mg on day 1, followed by a second dose of 400 mg on day 8. Similar to the first regimen, a third dose of 400 mg can be administered on day 15 if necessary. Again, the CD101 is administered as an aqueous pharmaceutical composition over a time period of 30 to 180 minutes.

Claim 2 specifies that the third dose is administered if mycological eradication and/or clinical cure is not achieved in the subject by day 15, or if the subject displays symptoms of a fungal infection on day 15.

Claim 3 mentions that the CD101 salt used in the method is CD101 acetate.

Lastly, claim 4 specifies that the invasive candidiasis being treated in this method is candidemia.

This patent provides a method for effectively treating invasive candidiasis, specifically candidemia, using CD101 in salt or neutral form. The two outlined treatment regimens offer flexibility in dosing, with the option to administer a third dose if necessary. The use of CD101 acetate as the salt form is also specified. This patent could potentially lead to improved treatment options for patients with invasive candidiasis, addressing a significant medical need.

To know more about GlobalData’s detailed insights on Cidara Therapeutics, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies